Personal information

No personal information available

Activities

Collapse all

Employment (1)

Mie University: Tsu, Mie, JP

2021-08-01 to present | Professor (Personalized Cancer Immunotherapy)
Employment
Source: Self-asserted source
Yoshihiro Miyahara

Education and qualifications (1)

Mie University: Tsu, Mie, JP

M.D., Ph.D. (The Second Internal Medicine)
Education
Source: Self-asserted source
Yoshihiro Miyahara

Funding (10)

Basic research toward the establishment of next-generation personalized TCR-T therapy

2022-04-01 to 2025-03-31 | Grant
Japan Society for the Promotion of Science (Tokyo, JP)
URL: https://app.dimensions.ai/details/grant/grant.12862010
GRANT_NUMBER: 22H02919
Source: Self-asserted source
Yoshihiro Miyahara via DimensionsWizard

Biomarker-based manufacture of MAGE-A4/CAR-T cell in immunotherapy for esophageal cancer

2021-04-01 to 2024-03-31 | Grant
Japan Society for the Promotion of Science (Tokyo, JP)
URL: https://app.dimensions.ai/details/grant/grant.9683763
GRANT_NUMBER: 21K08682
Source: Self-asserted source
Yoshihiro Miyahara via DimensionsWizard

MAGE-A4抗原を発現する切除不能進行・再発腫瘍に対するCAR-T細胞療法の医師主導第I相治験

2021-04-01 to 2024-03-31 | Grant
Japan Agency for Medical Research and Development (Tokyo, JP)
URL: https://app.dimensions.ai/details/grant/grant.12844249
GRANT_NUMBER:

21ck0106658h0001
Source: Self-asserted source
Yoshihiro Miyahara via DimensionsWizard

T cell optimization for effective CAR-T cell therapy to refractory esophageal cancer

2019-06-28 to 2022-03-31 | Grant
Japan Society for the Promotion of Science (Tokyo, JP)
URL: https://app.dimensions.ai/details/grant/grant.8537572
GRANT_NUMBER: 19K22655
Source: Self-asserted source
Yoshihiro Miyahara via DimensionsWizard

T細胞レセプター疑似抗体及びGITR細胞内ドメインを利用した革新的CAR-T細胞輸注療法の開発

2018-04-01 to 2021-03-31 | Grant
Japan Agency for Medical Research and Development (Tokyo, JP)
URL: https://app.dimensions.ai/details/grant/grant.9337996
GRANT_NUMBER:

20ck0106412h0003
Source: Self-asserted source
Yoshihiro Miyahara via DimensionsWizard

成人T細胞白血病/リンパ腫に対する遺伝子改変細胞輸注療法

2018-04-01 to 2020-03-31 | Grant
Japan Agency for Medical Research and Development (Tokyo, JP)
URL: https://app.dimensions.ai/details/grant/grant.9337564
GRANT_NUMBER:

19nk0101503h0002
Source: Self-asserted source
Yoshihiro Miyahara via DimensionsWizard

成人T細胞白血病/リンパ腫に対するT細胞受容体遺伝子導入リンパ球輸注療法の開発

2017-04-01 to 2018-03-31 | Grant
Japan Agency for Medical Research and Development (Tokyo, JP)
URL: https://app.dimensions.ai/details/grant/grant.9338563
GRANT_NUMBER:

17lm0203038h0001
Source: Self-asserted source
Yoshihiro Miyahara via DimensionsWizard

Development of effective combined immunotherapies by using a novel immune response detection method

2016-04-01 to 2019-03-31 | Grant
Japan Society for the Promotion of Science (Tokyo, JP)
URL: https://app.dimensions.ai/details/grant/grant.5911963
GRANT_NUMBER: 16K07168
Source: Self-asserted source
Yoshihiro Miyahara via DimensionsWizard

Therapeutic potintial of Tregs transduced with CEA specific CAR in sever asthma

2016-04-01 to 2019-03-31 | Grant
Japan Society for the Promotion of Science (Tokyo, JP)
URL: https://app.dimensions.ai/details/grant/grant.5908156
GRANT_NUMBER: 16K09533
Source: Self-asserted source
Yoshihiro Miyahara via DimensionsWizard

Analysis of differentiation mechanism of peripherally induced Foxp3 positive T cells for application to cancer treatment

2011-01-01 to 2013-12-31 | Grant
Japan Society for the Promotion of Science (Tokyo, JP)
URL: https://app.dimensions.ai/details/grant/grant.6066315
GRANT_NUMBER: 23501284
Source: Self-asserted source
Yoshihiro Miyahara via DimensionsWizard

Works (45)

A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.

International journal of cancer
2023-02 | Journal article
DOI: 10.1002/ijc.34453
PMID: 36727538
Contributors: Ishihara M; Nishida Y; Kitano S; Kawai A; Muraoka D; Momose F; Harada N; Miyahara Y; Seo N; Hattori H et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial.

BMJ open
2022-11 | Journal article
DOI: 10.1136/bmjopen-2022-065109
PMID: 36375974
PMC: PMC9664294
Contributors: Okumura S; Ishihara M; Kiyota N; Yakushijin K; Takada K; Kobayashi S; Ikeda H; Endo M; Kato K; Kitano S et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.

Journal for immunotherapy of cancer
2022-06 | Journal article
DOI: 10.1136/jitc-2021-003811
PMID: 35768164
PMC: PMC9244667
Contributors: Ishihara M; Kitano S; Kageyama S; Miyahara Y; Yamamoto N; Kato H; Mishima H; Hattori H; Funakoshi T; Kojima T et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

IL-17A Is the Critical Cytokine for Liver and Spleen Amyloidosis in Inflammatory Skin Disease.

International journal of molecular sciences
2022-05 | Journal article
DOI: 10.3390/ijms23105726
PMID: 35628531
PMC: PMC9147816
Contributors: Iida S; Nakanishi T; Momose F; Ichishi M; Mizutani K; Matsushima Y; Umaoka A; Kondo M; Habe K; Hirokawa Y et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy.

Cancer immunology, immunotherapy : CII
2022-04 | Journal article
DOI: 10.1007/s00262-022-03194-5
PMID: 35429246
Contributors: Nagata Y; Kageyama S; Ishikawa T; Kokura S; Okayama T; Abe T; Murakami M; Otsuka K; Ariyoshi T; Kojima T et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients.

Cancer immunology, immunotherapy : CII
2021-03 | Journal article
DOI: 10.1007/s00262-021-02892-w
PMID: 33751208
Contributors: Ishikawa T; Kageyama S; Miyahara Y; Okayama T; Kokura S; Wang L; Sato E; Yagita H; Itoh Y; Shiku H
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours.

BMC cancer
2020-06 | Journal article
DOI: 10.1186/s12885-020-07098-4
PMID: 32600281
PMC: PMC7325278
Contributors: Ishihara M; Kageyama S; Miyahara Y; Ishikawa T; Ueda S; Soga N; Naota H; Mukai K; Harada N; Ikeda H et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Relationship between T cell receptor clonotype and PD-1 expression of tumor-infiltrating lymphocytes in colorectal cancer.

European journal of immunology
2020-06 | Journal article
DOI: 10.1002/eji.201948399
PMID: 32441316
Contributors: Sukegawa K; Shitaoka K; Hamana H; Kobayashi E; Miyahara Y; Fujii K; Tsuda K; Saeki S; Nagata T; Ozawa T et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours

2020-05 | Preprint
DOI: 10.21203/rs.3.rs-16368/v2
PPR: PPR163386
Contributors: Ishihara M; Kageyama S; Miyahara Y; Ishikawa T; Ueda S; Soga N; Naota H; Mukai K; Harada N; Ikeda H et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.

Cancer immunology, immunotherapy : CII
2020-01 | Journal article
DOI: 10.1007/s00262-020-02483-1
PMID: 31980914
PMC: PMC7113205
Contributors: Ishihara M; Tono Y; Miyahara Y; Muraoka D; Harada N; Kageyama S; Sasaki T; Hori Y; Soga N; Uchida K et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Development of INSOL-tag for proteome-wide protein handling and its application in protein array analysis.

Genes to cells : devoted to molecular & cellular mechanisms
2019-12 | Journal article
DOI: 10.1111/gtc.12735
PMID: 31733161
Contributors: Fukuda E; Mori M; Shiku H; Miyahara Y; Kawamura Y; Ogawa K; Ogura T; Goshima N
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance.

The Journal of clinical investigation
2019-02 | Journal article
DOI: 10.1172/jci97642
PMID: 30628894
PMC: PMC6391090
Contributors: Muraoka D; Seo N; Hayashi T; Tahara Y; Fujii K; Tawara I; Miyahara Y; Okamori K; Yagita H; Imoto S et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer.

Case reports in oncology
2019-01 | Journal article
DOI: 10.1159/000496933
PMID: 31043953
PMC: PMC6477485
Contributors: Oda H; Ishihara M; Miyahara Y; Nakamura J; Kozuka Y; Iwasa M; Tsunoda A; Yamashita Y; Saito K; Mizuno T et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma.

Oncotarget
2018-11 | Journal article
DOI: 10.18632/oncotarget.26323
PMID: 30542513
PMC: PMC6267599
Contributors: Ueda S; Miyahara Y; Nagata Y; Sato E; Shiraishi T; Harada N; Ikeda H; Shiku H; Kageyama S
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination.

Blood
2018-07 | Journal article
DOI: 10.1182/blood-2017-08-802926
PMID: 30045840
PMC: PMC6148344
Contributors: Akahori Y; Wang L; Yoneyama M; Seo N; Okumura S; Miyahara Y; Amaishi Y; Okamoto S; Mineno J; Ikeda H et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Clinical Implications of CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup>Regulatory T Cell Frequencies After CHP-MAGE-A4 Cancer Vaccination.

Anticancer research
2018-03 | Journal article
DOI: 10.21873/anticanres.12368
PMID: 29491069
Contributors: Wada M; Tsuchikawa T; Kyogoku N; Abiko T; Miyauchi K; Takeuchi S; Kuwatani T; Shichinohe T; Miyahara Y; Kageyama S et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers.

Oncotarget
2018-02 | Journal article
DOI: 10.18632/oncotarget.24504
PMID: 29599915
PMC: PMC5871086
Contributors: Tono Y; Ishihara M; Miyahara Y; Tamaru S; Oda H; Yamashita Y; Tawara I; Ikeda H; Shiku H; Mizuno T et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Serum immunoglobulin E response as a marker for unfavorable prognosis following cholesteryl pullulan-MAGE A4 vaccination.

Oncology letters
2018-01 | Journal article
DOI: 10.3892/ol.2018.7767
PMID: 29467889
PMC: PMC5795923
Contributors: Abiko T; Tsuchikawa T; Miyauchi K; Wada M; Kyogoku N; Shichinohe T; Miyahara Y; Kageyama S; Ikeda H; Shiku H et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS.

Blood
2017-08 | Journal article
DOI: 10.1182/blood-2017-06-791202
PMID: 28860210
Contributors: Tawara I; Kageyama S; Miyahara Y; Fujiwara H; Nishida T; Akatsuka Y; Ikeda H; Tanimoto K; Terakura S; Murata M et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors.

Oncoimmunology
2017-03 | Journal article
DOI: 10.1080/2162402x.2017.1306617
PMID: 28638727
PMC: PMC5467990
Contributors: Fujii K; Miyahara Y; Harada N; Muraoka D; Komura M; Yamaguchi R; Yagita H; Nakamura J; Sugino S; Okumura S et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene-A4 nanogel.

Oncology letters
2016-10 | Journal article
DOI: 10.3892/ol.2016.5253
PMID: 28105158
PMC: PMC5228337
Contributors: Kyogoku N; Ikeda H; Tsuchikawa T; Abiko T; Fujiwara A; Maki T; Yamamura Y; Ichinokawa M; Tanaka K; Imai N et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Clinical relevance of antigen spreading pattern induced by CHP-MAGE-A4 cancer vaccination.

Immunotherapy
2016-02 | Journal article
DOI: 10.2217/imt-2016-0007
PMID: 26888315
Contributors: Miyauchi K; Tsuchikawa T; Wada M; Abiko T; Kyogoku N; Shichinohe T; Miyahara Y; Kageyama S; Ikeda H; Shiku H et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

2015 Guidance on cancer immunotherapy development in early-phase clinical studies.

Cancer science
2015-12 | Journal article
DOI: 10.1111/cas.12819
PMID: 26767933
PMC: PMC4714668
Contributors: Guidance Development Review Committee; Working Group for Clinical Studies of Cancer Immunotherapy; Working Group for Effector Cell Therapy; Biostatistics Subcommittee
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research
2015-04 | Journal article
DOI: 10.1158/1078-0432.ccr-14-1559
PMID: 25855804
Contributors: Kageyama S; Ikeda H; Miyahara Y; Imai N; Ishihara M; Saito K; Sugino S; Ueda S; Ishikawa T; Kokura S et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

PD-1-dependent restoration of self-tolerance in the NOD mouse model of diabetes after transient anti-TCRβ mAb therapy.

Diabetologia
2015-03 | Journal article
DOI: 10.1007/s00125-015-3564-1
PMID: 25794782
Contributors: Schroder PM; Khattar M; Baum CE; Miyahara Y; Chen W; Vyas R; Muralidharan S; Mierzejewska B; Stepkowski SM
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Interleukin-21 is a critical regulator of CD4 and CD8 T cell survival during priming under Interleukin-2 deprivation conditions.

PloS one
2014-01 | Journal article
DOI: 10.1371/journal.pone.0085882
PMID: 24416451
PMC: PMC3887105
Contributors: Khattar M; Miyahara Y; Schroder PM; Xie A; Chen W; Stepkowski SM
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients.

Journal of translational medicine
2013-10 | Journal article
DOI: 10.1186/1479-5876-11-246
PMID: 24093426
PMC: PMC4015172
Contributors: Kageyama S; Wada H; Muro K; Niwa Y; Ueda S; Miyata H; Takiguchi S; Sugino SH; Miyahara Y; Ikeda H et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

A dynamic dual role of IL-2 signaling in the two-step differentiation process of adaptive regulatory T cells.

Journal of immunology (Baltimore, Md. : 1950)
2013-02 | Journal article
DOI: 10.4049/jimmunol.1200751
PMID: 23427250
PMC: PMC3608742
Contributors: Guo Z; Khattar M; Schroder PM; Miyahara Y; Wang G; He X; Chen W; Stepkowski SM
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

In vivo persistence of adoptively transferred TCR gene-transduced lymphocytes with anti-tumor reactivity in patients with MAGE-A4 expressing esophageal cancer

Journal for immunotherapy of cancer
2013-01 | Journal article
DOI: 10.1186/2051-1426-1-s1-o3
PMC: PMC3991198
Contributors: Ikeda H; Kageyama S; Imai N; Miyahara Y; Ishihara M; Katayama N; Yoshioka H; Tomura D; Nukaya I; Mineno J et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Intratumoral injection of Propionibacterium acnes suppresses malignant melanoma by enhancing Th1 immune responses.

PloS one
2011-12 | Journal article
DOI: 10.1371/journal.pone.0029020
PMID: 22216160
PMC: PMC3244427
Contributors: Tsuda K; Yamanaka K; Linan W; Miyahara Y; Akeda T; Nakanishi T; Kitagawa H; Kakeda M; Kurokawa I; Shiku H et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

IL-2-deprivation and TGF-beta are two non-redundant suppressor mechanisms of CD4+CD25+ regulatory T cell which jointly restrain CD4+CD25- cell activation.

Immunology letters
2010-06 | Journal article
DOI: 10.1016/j.imlet.2010.06.001
PMID: 20570629
PMC: PMC2922908
Contributors: Wang G; Khattar M; Guo Z; Miyahara Y; Linkes SP; Sun Z; He X; Stepkowski SM; Chen W
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

"Default" generation of neonatal regulatory T cells.

Journal of immunology (Baltimore, Md. : 1950)
2010-05 | Journal article
DOI: 10.4049/jimmunol.0903806
PMID: 20498359
Contributors: Wang G; Miyahara Y; Guo Z; Khattar M; Stepkowski SM; Chen W
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

IL-7, but not thymic stromal lymphopoietin (TSLP), during priming enhances the generation of memory CD4+ T cells.

Immunology letters
2010-01 | Journal article
DOI: 10.1016/j.imlet.2009.12.019
PMID: 20064560
Contributors: Guo Z; Wang G; Miyahara Y; Khattar M; Linkes SP; Wang C; Xia J; Pan Y; Chen W; He X et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer.

Proceedings of the National Academy of Sciences of the United States of America
2008-10 | Journal article
DOI: 10.1073/pnas.0710686105
PMID: 18832156
PMC: PMC2563129
Contributors: Miyahara Y; Odunsi K; Chen W; Peng G; Matsuzaki J; Wang RF
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Tumor-associated galectin-3 modulates the function of tumor-reactive T cells.

Cancer research
2008-09 | Journal article
DOI: 10.1158/0008-5472.can-08-1245
PMID: 18757439
PMC: PMC3181121
Contributors: Peng W; Wang HY; Miyahara Y; Peng G; Wang RF
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research
2007-12 | Journal article
DOI: 10.1158/1078-0432.ccr-07-0842
PMID: 18056169
Contributors: Kiniwa Y; Miyahara Y; Wang HY; Peng W; Peng G; Wheeler TM; Thompson TC; Old LJ; Wang RF
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan.

Clinical cancer research : an official journal of the American Association for Cancer Research
2006-12 | Journal article
DOI: 10.1158/1078-0432.ccr-06-1546
PMID: 17189412
Contributors: Kitano S; Kageyama S; Nagata Y; Miyahara Y; Hiasa A; Naota H; Okumura S; Imai H; Shiraishi T; Masuya M et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

T-cell receptor and nucleic acid encoding the receptor

2006-09 | Patent
OTHER-ID:

CN101287831
Contributors: HIROSHI SHIKU; ATSUNORI HIASA; SATOSHI OKUMURA; HIROAKI NAOTA; YOSHIHIRO MIYAHARA
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Generation of peptide-specific CD8+ T cells by phytohemagglutinin-stimulated antigen-mRNA-transduced CD4+ T cells.

Journal of immunological methods
2006-06 | Journal article
DOI: 10.1016/j.jim.2006.05.009
PMID: 16828790
Contributors: Naota H; Miyahara Y; Okumura S; Kuzushima K; Akatsuka Y; Hiasa A; Kitano S; Takahashi T; Yuta A; Majima Y et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE.

Clinical cancer research : an official journal of the American Association for Cancer Research
2005-08 | Journal article
DOI: 10.1158/1078-0432.ccr-04-2585
PMID: 16061876
Contributors: Miyahara Y; Naota H; Wang L; Hiasa A; Goto M; Watanabe M; Kitano S; Okumura S; Takemitsu T; Yuta A et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

A novel role for Notch ligand Delta-1 as a regulator of human Langerhans cell development from blood monocytes.

Journal of leukocyte biology
2005-07 | Journal article
DOI: 10.1189/jlb.1204746
PMID: 16037408
Contributors: Hoshino N; Katayama N; Shibasaki T; Ohishi K; Nishioka J; Masuya M; Miyahara Y; Hayashida M; Shimomura D; Kato T et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Essential roles of tumor-derived helper T cell epitopes for an effective peptide-based tumor vaccine.

Cancer immunity
2003-11 | Journal article
PMID: 14629132
Contributors: Wang L; Miyahara Y; Kato T; Wang L; Aota T; Kuribayashi K; Shiku H
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Rapid lethality of hosts by interleukin-12 following H-2 compatible allogeneic bone marrow transplantation: Reminiscence of gut-associated acute graft-versus-host reaction.

International journal of oncology
2002-10 | Journal article
PMID: 12239618
Contributors: Schmitt M; Taniguchi M; Yoshida T; Miyahara Y; Gu X; Mukai K; Yagita H; Dohner H; Shiku H
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

[CTL and helper epitopes in DNA vaccines].

[Rinsho ketsueki] The Japanese journal of clinical hematology
2002-05 | Journal article
PMID: 12096490
Contributors: Nishikawa H; Ikeda H; Itakura M; Miyahara Y; Aota T; Muko K; Watanabe M; Tamaki H
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central

Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity.

Proceedings of the National Academy of Sciences of the United States of America
2001-11 | Journal article
DOI: 10.1073/pnas.251547298
PMID: 11724951
PMC: PMC64723
Contributors: Nishikawa H; Tanida K; Ikeda H; Sakakura M; Miyahara Y; Aota T; Mukai K; Watanabe M; Kuribayashi K; Old LJ et al.
Source: Self-asserted source
Yoshihiro Miyahara via Europe PubMed Central
How many people are using ORCID?